Trials / Completed
CompletedNCT01358175
16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 371 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the efficacy and safety of secukinumab in patients with active ankylosing spondylitis who are intolerant to or have had an inadequate response to NSAIDs, DMARDs and / or TNFα inhibitor therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Secukinumab (75 mg) | Secukinumab (75 mg) |
| DRUG | Secukinumab (150 mg) | Secukinumab (150 mg) |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2011-05-23
- Last updated
- 2017-03-09
- Results posted
- 2017-01-27
Locations
67 sites across 14 countries: United States, Belgium, Bulgaria, Canada, France, Germany, Italy, Mexico, Netherlands, Peru, Russia, Taiwan, Turkey (Türkiye), United Kingdom
Source: ClinicalTrials.gov record NCT01358175. Inclusion in this directory is not an endorsement.